DelMar PHARMACEUTICALS

Vancouver, BC | Menlo Park, CA

Corporate Overview

Q2 2011

Company Overview

- **Founded in 2010**
- **Rapidly developing & commercializing proven cancer therapies in orphan indications for patients failing modern biologic therapy**
- **VAL-083: First product opportunity**
  - U.S. IND filed Q4'10 : GBM (post-Avastin failure)
  - Second orphan indication defined
  - Four new patents filed 2009/10
- **Significant near-term revenue potential**
  - International markets where drug is already approved
- **Defined pipeline expansion opportunities**
- **Experienced corporate & drug development team on board**
- **Seeking $5m in new capital**

Achievements Since Inception

- Acquired VAL-083 technology
- Filed IND with U.S. FDA
- Developed novel route of synthesis
- Completed Seed Financing
- Filed Four New patents
- Received NRC-IRAP grant award

Teaching Old Drugs New Tricks

Company / Origination	Product	Impact
cti *China*	**Trisenox™** *arsenic trioxide* *NSCLC - 706363*	✓ ***Approved for refractory APL (2000)*** ✓ ***Acquired (2005) $100m***
salmedix *East Germany*	**Treanda™** *Bendamustine* *NSCLC - 738783*	✓ ***Approved for refractory NHL (2008)*** ✓ ***Acquired (2005) - $200m*** ✓ ***Annual sales (2009) >$400m***
ChemGenex Pharmaceuticals *China*	**Omapro™** *Omacetaxine* *NSCLC - 141633*	✓ ***Approval pending for refractory CML*** ✓ ***Partnered (2009) - $125m*** ✓ ***Option to acquire control (2010) - >$200m***
DelMar Pharmaceuticals *China*	**VAL-083** NSCLC - undisclosed	✓ ***IND filed: refractory GBM*** ✓ ***Second target indication: AML***

Lead Product Candidate: VAL-083

Drug Profile

- Small-molecule chemotherapeutic
  - First-in-class chemistry
- Well characterized mechanism of action
  - Bi-functional akylating agent
  - Not cross resistant to current therapies
- Validated in more than 40 human clinical trials (NCI) / Commercial product in China
  - Demonstrated efficacy in multiple tumor types
- Pharmacokinetics/Pharmacodynamics
  - Orally bioavailable
  - Rapidly enters CNS with long half-life in CNS
  - Selective for brain tumors vs. intact white matter

VAL-083:
Technical Advantages & Risk Reduction

- Proven safety & efficacy profile
- Established commercial-scale manufacturing
- Streamlined regulatory pathway
- Highly attractive pricing & reimbursement
- Strategy to generate near-term revenue from international markets where the drug is already approved
- Highly experienced team

VAL-083: Development Strategy



12 Month Milestones

Key Milestone	Target Date
Enroll first patient in our Phase II GBM Clinical Trial	H1 2011
Confirm strategy for near-term revenue (China)	H1 2011
Obtain Orphan Drug Designation	H1 2011
Complete a minimum US$3m Financing	H1 2011
Interim data – Phase II GBM Clinical Trial	H2 2011
Prepare IND for 2nd indication	H2 2011
Preliminary efficacy data Phase II GBM study	H2 2011

Del Mar Pharmaceuticals

Jeffrey Bacha, B.Sc., MBA – President & CEO

- jbacha@delmarpharma.com
- +1 604 317 7022

Corporate Headquarters:
Suite 400 - 1727 West Broadway
Vancouver, British Columbia
Canada V6J 4W6

Clinical Operations:
3475 Edison Way, Suite R
Menlo Park, California 94025
USA